Market revenue in 2023 | USD 461.4 million |
Market revenue in 2030 | USD 1,029.6 million |
Growth rate | 12.2% (CAGR from 2023 to 2030) |
Largest segment | Reagents |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Reagents, Kits, Instruments, Enzymes, Services |
Key market players worldwide | Roche Holding AG, Thermo Fisher Scientific Inc, Eisai Co Ltd, Novartis AG ADR, Element Biosciences, Dovetail Genomics, Illumina Inc, Promega, Abcam PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epigenetics market will help companies and investors design strategic landscapes.
Reagents was the largest segment with a revenue share of 35.15% in 2023. Horizon Databook has segmented the Spain epigenetics market based on reagents, kits, instruments, enzymes, services covering the revenue growth of each sub-segment from 2018 to 2030.
Spain has a strong academic & research infrastructure, with institutions such as the Centre for Genomic Regulation (CRG) and the National Centre for Biotechnology (CNB) actively researching epigenetics applications in various fields, including healthcare, agriculture, & environmental remediation. Several Spanish startups are entering into the genetic therapies market and are developing & commercializing innovative solutions.
For instance, In June 2021, Viralgen Vector Core, a Spanish Contract Development and Manufacturing Organization (CDMO), inaugurated the first module of its new manufacturing facility in San Sebastian, Spain, with a substantial investment of €70 million (USD 85.4 million). The facility is dedicated to the production of clinical and commercial Recombinant Adeno-Associated Virus (rAAV) vectors for gene therapies, utilizing the Pro10 cell line.
This facility is certified to comply with Good Manufacturing Practice (GMP) standards. With the addition of this new module, Viralgen operates two facilities with seven single-use suites, providing a combined manufacturing capacity of up to 2,000 liters. This development emphasizes Spain's commitment to advancing capabilities in gene therapy and positions the country as a significant contributor to the growing field of genetic & molecular research.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain epigenetics market , including forecasts for subscribers. This country databook contains high-level insights into Spain epigenetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account